Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 1
2004 4
2005 2
2006 5
2007 4
2008 4
2009 3
2010 2
2011 4
2012 3
2013 4
2014 3
2015 5
2016 13
2017 5
2018 9
2019 4
2020 4
2021 2
2022 6
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. Chinot OL, et al. Among authors: saran f. N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345. N Engl J Med. 2014. PMID: 24552318 Free article. Clinical Trial.
SIOPE - Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy.
Ajithkumar T, Horan G, Padovani L, Thorp N, Timmermann B, Alapetite C, Gandola L, Ramos M, Van Beek K, Christiaens M, Lassen-Ramshad Y, Magelssen H, Nilsson K, Saran F, Rombi B, Kortmann R, Janssens GO; SIOPE BTG Radiotherapy Group. Ajithkumar T, et al. Among authors: saran f. Radiother Oncol. 2018 Aug;128(2):192-197. doi: 10.1016/j.radonc.2018.04.016. Epub 2018 May 2. Radiother Oncol. 2018. PMID: 29729847
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Weller M, et al. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28844499 Free article. Clinical Trial.
MGMT promoter methylation status: time for a frank discussion.
Coleman N, Bridges L, Saran F. Coleman N, et al. Among authors: saran f. J Neurooncol. 2017 Jul;133(3):667-668. doi: 10.1007/s11060-017-2483-z. Epub 2017 May 30. J Neurooncol. 2017. PMID: 28560662 No abstract available.
Recent advances in paediatric neuro-oncology.
Saran F. Saran F. Curr Opin Neurol. 2002 Dec;15(6):671-7. doi: 10.1097/01.wco.0000044762.39452.e3. Curr Opin Neurol. 2002. PMID: 12447104 Review.
84 results